Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 10Sarcoma, Alveolar Soft Part 3Breast Neoplasms 3Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Neoplasms 2Melanoma 2Head and Neck Neoplasms 2Gliosarcoma 2Glioblastoma 2Vulvar Neoplasms 1Urogenital Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pancreatic Neoplasms 1Obesity 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Lymphoma, Follicular 1Lung Neoplasms 1Liposarcoma, Myxoid 1Liposarcoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1

Interventions

Doxorubicin 17Cyclophosphamide 16Ifosfamide 11fludarabine 9Radiotherapy 8tazemetostat 5pembrolizumab 4pazopanib 4Gemcitabine 4pegfilgrastim 3cixutumumab 3Trabectedin 3Radiation 3Imatinib Mesylate 3Filgrastim 3Docetaxel 3Dacarbazine 3sargramostim 2liposomal doxorubicin 2fludarabine phosphate 2brostallicin 2aldesleukin 2X-Rays 2Sunitinib 2Specimen Handling 2Sorafenib 2Radiation Dose Hypofractionation 2Quality of Life 2Nivolumab 2Molecular Diagnostic Techniques 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Synovial × atezolizumab × Sarcoma × Clear all
NCT02609984 2020-07-07

IMDZ-C232

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Terminated
89 enrolled 24 charts
Sarcoma

Liposarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡